two
previou
issu
describ
talk
molecular
virolog
workshop
first
two
day
annual
clinic
virolog
symposium
cv
april
latter
attend
clinic
virologist
other
interest
field
meet
organ
pan
american
societi
clinic
virolog
pascv
univers
south
florida
colleg
medicin
put
togeth
two
decad
group
dedic
peopl
like
workshop
cv
session
character
high
qualiti
focu
present
live
question
answer
session
least
pleasant
meet
locat
modest
older
hotel
beauti
gulf
mexico
beach
cv
distinguish
workshop
addit
poster
exhibit
panel
discuss
format
present
cd
audio
portion
lectur
discuss
avail
intelliquest
media
inc
wwwintelliquestmediacom
final
section
report
offer
brief
descript
session
last
day
meet
cover
topic
rang
updat
detect
treatment
sever
virus
case
present
technolog
treatis
vaccin
develop
diseas
erad
effort
learn
opportun
mani
intens
session
could
walk
beach
rumin
day
lesson
michael
fri
md
mf
univers
north
carolina
chapel
hill
nc
gave
fredrich
deinhardt
lectureship
speak
hepat
c
viru
evolv
guidelin
paradigm
cite
cdc
data
indic
men
women
us
year
old
infect
describ
recent
therapeut
breakthrough
result
cure
rate
otherwis
larg
chronic
infect
cure
defin
undetect
hcv
rna
normal
alt
month
treatment
patient
relaps
although
reason
differ
understood
clear
hcv
genotyp
major
factor
respons
therapi
thu
pretreat
genotyp
determin
mandatori
us
case
genotyp
lower
averag
respons
rate
genotyp
requir
extens
treatment
mf
studi
show
twolog
reduct
viral
load
week
therapi
predict
sustain
respons
week
therapi
patient
infect
hcv
genotyp
wherea
failur
achiev
twolog
reduct
predict
treatment
failur
thu
current
treatment
paradigm
consist
initi
genotyp
viral
load
determin
follow
retest
hcv
viral
load
week
treatment
genotyp
patient
twolog
reduct
achiev
treatment
stop
hcv
rna
undetect
treatment
continu
week
without
test
hcv
rna
detect
test
repeat
week
treatment
point
hcv
rna
still
detect
treatment
stop
hcv
rna
undetect
treatment
continu
week
patient
genotyp
get
week
treatment
without
interim
hcv
rna
test
achiev
sustain
respons
rate
minim
treatment
durat
import
limit
side
effect
effici
use
resourc
discuss
follow
point
brought
hcv
core
antigen
test
suffici
sensit
use
marker
earli
virolog
respons
limit
detect
roughli
equival
copiesml
hcv
rna
third
hiv
patient
coinfect
hcv
treatment
side
effect
pronounc
sustain
respons
rate
encount
mix
genotyp
infect
treat
resist
genotyp
sustain
respond
hcv
seem
clear
even
liver
tissu
children
expos
via
blood
clear
hcv
spontan
sara
miller
phd
sm
duke
univers
medic
center
durham
nc
report
detect
virus
clinic
specimen
use
electron
microscopi
em
first
use
late
em
extens
use
difficult
viral
diagnosi
gold
standard
detect
identif
new
pathogen
em
identifi
emerg
diseas
agent
sar
coronaviru
monkeypox
viru
nipah
viru
hendra
viru
ebola
viru
case
pathogen
unknown
unsuspect
prior
inform
requir
analysi
compar
molecular
method
molecular
method
becom
sensit
em
past
decad
em
requir
expens
instrument
train
personnel
still
fastest
method
detect
viral
pathogen
requir
cultiv
agent
sm
lab
test
approxim
specimensyear
virus
fluid
cell
solid
tissu
specimen
diarrheal
stool
gastroenter
patient
sinc
enter
virus
grow
grow
slowli
cell
cultur
em
test
provid
advantag
urin
examin
polyomaviru
sinc
peopl
expos
polyomaviru
age
posit
antibodi
sm
frequent
monitor
urin
noninvas
specimen
kidney
transplant
patient
prone
contract
polyomaviru
may
reactiv
virus
contribut
organ
reject
activ
immun
system
thu
increas
requir
antireject
drug
commonli
seen
polyomavirus
bk
jc
cultiv
current
detect
possibl
em
sm
found
virus
caus
agent
folliculocentr
skin
infect
immunocompromis
host
neg
stain
specimen
stool
suspens
tear
urin
rapid
min
use
electron
dens
heavi
metal
salt
solut
wide
use
em
techniqu
liquid
specimen
routin
concentr
tabletop
ultracentrifug
add
min
prepar
em
valuabl
detect
adventiti
virus
tissu
cultur
particularli
use
examin
unknown
unsuspect
agent
bioterror
surveil
detect
emerg
diseas
christin
ginocchio
phd
cg
north
shore
lij
center
health
system
lab
lake
success
ny
talk
human
papillomaviru
hpv
provid
comprehens
updat
hpv
diagnost
human
papillomavirus
belong
famili
papovavirida
caus
agent
differ
wart
hpv
first
link
human
cancer
harald
zur
hausen
germani
recogn
tumor
viru
major
caus
cervic
carcinoma
adenocarcinoma
hpv
common
sexual
transmit
agent
male
femal
also
transmit
mother
child
estim
incid
new
infect
millionyear
us
infect
spontan
clear
women
older
year
persist
carrier
hpv
incid
mortal
decreas
us
recent
year
approxim
deathsyear
current
due
cervic
cancer
make
third
common
caus
cancer
women
tumor
progress
believ
occur
stage
first
infect
basal
epitheli
cell
activ
infect
subclin
latenc
final
advanc
tumor
benign
hyperplast
premalign
malign
progress
cancer
hpv
infect
occur
due
block
tumor
suppressor
protein
rb
interact
hpv
protein
viru
may
either
integr
host
dna
mostli
found
cancer
found
episom
subclin
latenc
cervic
tumor
viru
integr
two
hundr
hpv
genotyp
known
associ
cervic
intraepitheli
neoplasia
cin
divid
three
categori
unspecifi
low
risk
high
risk
high
risk
genotyp
greatest
associ
cervic
carcinoma
women
posit
develop
cin
grade
within
year
cervic
cancer
tradit
diagnos
cytolog
pap
smear
papanicoleau
stain
smear
accord
bethesda
classif
system
acog
american
colleg
obstetrician
gynecologist
recommend
sensit
detect
high
grade
squamou
intraepitheli
lesion
hsil
shown
enhanc
addit
hpv
dna
test
cytolog
cytolog
plu
hpv
dna
test
thu
us
fda
food
drug
administr
approv
combin
cervic
cytolog
hpv
dna
test
primari
screen
women
age
year
older
system
hpv
dna
detect
includ
situ
hybrid
benchmark
inform
hpv
system
ventana
medic
system
tuscon
az
dako
genpoint
tm
system
trapp
franc
inpath
tm
molecular
diagnost
invirion
frankfurt
germani
nasbabas
pretect
hpv
proofer
norchip
norway
liquid
hybrid
digen
hybrid
captur
hpv
dna
test
variou
pcr
amplif
detect
method
roch
hpv
line
blot
roch
diagnost
ruo
home
brew
applic
hpv
asr
analyt
specif
reagent
cg
also
provid
summari
refer
sever
test
method
method
evalu
see
castl
et
al
clavel
et
al
gravitt
et
al
gray
walzer
menez
et
al
pretet
et
al
qureshi
et
al
solomon
et
al
wright
et
al
acog
practic
bulletin
vol
august
goal
combin
test
provid
effect
tool
diagnosi
manag
cervic
dysplasia
identifi
women
risk
progress
diseas
detect
cancer
earli
reduc
number
unnecessari
colposcopi
gregori
storch
md
gs
st
loui
children
hospit
st
loui
mo
discuss
histori
diagnosi
human
polyomaviru
infect
begin
discoveri
mous
polyomaviru
follow
identif
rhesu
monkey
kidney
cell
use
product
polio
vaccin
famili
polyomavirida
known
member
includ
human
virus
jcv
bkv
name
initi
person
first
isol
polyomavirus
found
worldwid
narrow
host
rang
transform
cell
line
cultur
caus
tumor
experiment
anim
small
kb
ds
doubl
strand
circular
dna
encod
variou
protein
larg
antigen
small
antigen
agnoprotein
structur
protein
antigen
play
crucial
function
role
multipl
enzymat
activ
interact
host
protein
see
also
hess
brandner
serolog
studi
shown
human
infect
virus
occur
childhood
although
rout
transmiss
unknown
seroposit
increas
age
jcv
bkv
circul
independ
viru
may
persist
variou
site
bodi
includ
kidney
brain
lymphocyt
may
reactiv
pregnanc
immunosuppress
human
diseas
pml
progress
multifoc
leucoencephalopathi
link
jcv
bkv
link
hemorrhag
cystiti
urethr
stenosi
transplant
nephropathi
may
link
differ
brain
tumor
focal
segment
glomerulosclerosi
infect
pediatr
kidney
transplant
recipi
laboratori
diagnosi
base
cell
cultur
practic
pcr
serolog
bkv
first
found
associ
kidney
transplant
nephropathi
tn
progress
allograft
failur
bkvassoci
tn
diagnos
papanicoleau
stain
decoy
cell
urin
show
viral
nuclear
inclus
quantif
viral
load
plasma
quantit
pcr
low
dose
cidofovir
nephrotox
andor
reduct
immunosuppress
increas
risk
transplant
reject
current
treatment
choic
bkv
also
found
hemorrhag
cystiti
bone
marrow
hematopoiet
stem
cell
transplant
recipi
monitor
bkv
urin
relev
viremia
bkv
realtim
assay
present
investig
develop
respect
male
present
day
tick
bite
femal
week
gestat
present
abdomin
pain
fever
nausea
vomit
undergo
emerg
caesarian
section
due
fetal
distress
day
hospit
boy
aplast
anemia
tcell
deplet
mismatch
stem
cell
transplant
sister
present
persist
cough
two
month
later
weight
loss
chest
pain
nausea
vomit
tachypn
boy
sickl
cell
diseas
receiv
monthli
red
cell
transfus
secondari
stroke
prevent
present
fever
mild
scleral
icteru
man
travel
vladivostock
russia
present
respiratori
ill
russia
week
return
sever
headach
day
later
becom
confus
incoher
speech
develop
fever
nausea
vomit
boy
develop
nasal
discharg
cough
fussi
present
fever
tachycardia
puls
present
discuss
took
place
two
hour
author
believ
could
adequ
cover
full
session
includ
audio
cdrom
describ
audienc
panel
present
interact
discuss
differ
potenti
pathogen
variou
test
test
method
therapi
tri
find
consensu
stateoftheart
procedur
final
lead
diagnosi
robert
dom
md
phd
rd
univers
pennsylvania
philadelphia
pa
describ
progress
toward
develop
entri
inhibitor
new
type
drug
hiv
high
replic
rate
high
transcript
error
rate
character
hiv
make
move
target
drug
develop
statist
everi
base
viral
genom
mutat
everi
possibl
base
everi
day
untreat
individu
current
drug
target
one
two
viral
enzym
revers
transcriptas
proteas
one
fusion
inhibitor
recent
approv
integras
third
viral
enzym
difficult
target
hiv
envelop
viru
entri
cell
involv
attach
receptor
engag
trigger
event
phdepend
independ
conform
chang
membran
fusion
trigger
event
hiv
phindepend
engag
coreceptor
hiv
receptor
coreceptor
earli
later
switch
viru
associ
acceler
diseas
progress
polymorph
prevent
hiv
entri
cell
protect
homozygot
hiv
infect
suggest
good
drug
target
inhibitor
develop
opportun
hiv
entri
inhibit
exploit
four
point
along
pathway
block
nativ
envelop
protein
trimer
block
bind
step
block
coreceptor
bind
block
bundl
format
membran
fusion
enfuvirtid
peptid
fusion
inhibitor
work
last
step
addit
entri
inhibitor
list
treatment
option
mean
viral
phenotyp
becom
import
addit
much
viru
clinician
need
know
kind
viru
present
ie
coreceptor
viru
use
research
also
observ
differ
viru
strain
cell
differ
donor
lead
much
larger
variabl
potenc
entri
inhibitor
order
magnitud
variabl
seen
type
hiv
drug
variat
lead
addit
test
requir
drug
avail
clinic
use
case
could
made
patient
take
enfuvirtid
genotyp
polymorph
instanc
rd
review
mechan
action
studi
sensit
data
enfuvirtid
sever
candid
entri
inhibitor
drug
describ
viru
host
cell
factor
affect
drug
sensit
practic
implic
discuss
point
includ
fact
chemokin
natur
ligand
protect
effect
hiv
diseas
progress
virus
less
preval
reason
mysteri
express
level
infectionr
limit
level
patient
make
antibodi
enfuvirtid
despit
expos
larg
amount
presenc
inhibitor
hiv
evolv
use
differ
way
rather
use
instead
switch
coreceptor
use
take
place
kill
use
fusion
inhibitor
entri
inhibitor
may
find
applic
envelop
virus
phindepend
trigger
event
kenneth
bern
md
phd
kb
univers
florida
medic
center
gainesvil
fl
report
adenoassoci
viru
aav
vehicl
gene
therapi
begin
point
unlik
other
potenti
use
viru
rather
pathogen
fact
although
peopl
antibodi
aav
caus
known
diseas
aav
belong
famili
parvovirida
need
anoth
helper
viru
either
adenoviru
herp
viru
replic
linear
kb
ssdna
encod
orf
open
read
frame
result
express
regulatori
protein
addit
structur
protein
encod
anoth
larg
orf
gene
flank
invert
termin
repeat
base
long
aav
produc
progeni
virus
presenc
helper
virus
absenc
replic
cell
divis
viru
persist
year
may
protect
role
women
cervic
cancer
aav
viru
known
integr
host
dna
sitespecif
nucleotid
stretch
human
chromosom
properti
exploit
gene
therapi
aav
use
vector
introduc
new
gene
intern
viral
sequenc
replac
new
target
gene
appropri
regulatori
sequenc
origin
termin
end
sequenc
remain
sequenc
requir
packag
viral
coat
stabil
dna
within
cell
gener
doublestrand
dna
packag
size
transgen
may
exceed
kb
aav
vector
test
varieti
model
system
limit
number
clinic
trial
involv
patient
cystic
fibrosi
factor
ix
defici
kb
report
aav
gene
therapi
involv
diseas
eye
agerel
macular
degener
amd
diabet
retinopathi
use
aav
vector
mous
model
frederick
g
hayden
phd
fh
univers
virginia
charlottesvil
va
discuss
intranas
vaccin
influenza
prevent
children
master
donor
strain
contain
attenu
mutat
caiv
coldadapt
influenza
vaccin
develop
viru
liveattenu
coldadapt
c
temperatur
sensit
c
show
greater
reduct
replic
combin
donor
viru
ha
na
gene
segment
wildtyp
antigen
variant
result
caiv
upon
applic
caiv
nasal
igg
elicit
well
system
ctl
influenzaspecif
immun
respons
two
dose
requir
fh
report
trial
children
age
month
copd
chronic
obstruct
pulmonari
diseas
patient
work
age
elderli
adult
seroneg
children
infecti
dose
children
pfuchild
pfustrain
could
toler
shed
low
pfuml
day
persontoperson
transmiss
rare
observ
nasal
throat
swab
specimen
test
yield
influenza
viru
unchang
vaccin
viru
genotyp
phenotyp
caiv
shed
healthi
adult
hiv
patient
patient
copd
maximum
last
longer
week
anoth
studi
almost
children
age
year
advers
side
effect
acut
respiratori
asthma
system
bacteri
acut
gastroenter
signific
compar
placebo
group
rhinorrhea
frequent
observ
fever
found
small
percentag
within
day
vaccin
compar
result
observ
also
vaccin
adult
fh
also
cover
safeti
efficaci
aspect
immunosuppress
individu
contact
caivt
trial
vaccin
health
care
worker
low
titer
recover
viru
detect
log
tcid
ml
children
hid
human
infecti
dose
serosuscept
log
tcid
ml
children
log
tcid
ml
adult
caiv
trial
south
africa
ambulatori
older
adult
year
efficaci
cultureposit
influenza
effect
result
overal
efficaci
fh
report
supplement
caiv
copd
patient
add
signific
efficaci
phase
iii
trial
trival
caiv
b
two
dose
intranas
spray
week
apart
children
month
year
protect
efficaci
high
b
one
year
data
studi
present
led
conclus
caiv
easi
administ
nasal
spray
versu
inject
induc
iga
serum
igg
specif
ctl
respons
efficaci
compar
inject
vaccin
adult
possibl
superior
trival
inactiv
vaccin
young
children
use
limit
us
fda
approv
caiv
healthi
adult
age
year
high
mainten
cost
frozen
vaccin
cold
chain
transmiss
risk
sever
formul
inactiv
intranas
vaccin
packag
liposom
proteosom
carbohydr
biopolym
current
investig
peter
strebel
md
ps
center
diseas
control
prevent
atlanta
ga
describ
continu
effort
measl
erad
measl
burden
estim
death
four
fundament
criteria
diseas
erad
program
human
critic
transmiss
sensit
specif
diagnost
must
avail
effect
intervent
must
possibl
must
possibl
demonstr
prolong
interrupt
larg
geograph
area
measl
criteria
met
human
major
reservoir
measl
viru
popul
group
greater
sever
hundr
thousand
requir
sustain
transmiss
serolog
assay
high
sensit
specif
measl
igm
exist
viru
isol
identifi
laboratori
vaccin
exist
highli
effect
develop
countri
strategi
develop
intervent
surveil
demonstr
progress
measl
erad
achiev
europ
africa
america
erad
achiev
measl
elimin
strategi
us
began
aim
high
vaccin
coverag
age
one
year
high
coverag
school
entri
care
surveil
aggress
outbreak
control
case
us
import
link
import
case
unlink
africa
measl
mortal
significantli
reduc
year
immun
program
vaccin
million
children
avert
estim
death
annual
summari
major
progress
made
measl
essenti
elimin
america
program
track
reduct
mortal
worldwid
goal
worldwid
erad
howev
polio
erad
higher
prioriti
